Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial - Phytother Res. 2016 Jun 8 - "patients with ultrasonographic evidence of NAFLD were randomly assigned to receive an amorphous dispersion  curcumin formulation (500 mg/day equivalent of 70-mg curcumin) or matched placebo for a period of 8 weeks ... Compared with placebo, curcumin was associated with a significant reduction in liver fat content (78.9% improvement in the curcumin vs 27.5% improvement in the placebo group). There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group. Curcumin was safe and well tolerated during the course of trial" - See curcumin products at Amazon.com.